Search
Avita Medical's ReCell regenerative medicine technology.

Avita seeks US market pre-approval

Health technology company Avita Medical has submitted a pre-market approval application to the US Food and Drug Administration for its ReCell regenerative medicine technology.

Login

(existing subscribers)

The password field is case sensitive.
Request new password

Add your comment

Share Price

Closing price for the last 90 trading days
Powered by Morningstar ®

Top 10 Shareholders

Substantial shareholders as published in the annual report.
Powered by Morningstar ®

Total Shareholder Return as at 31/12/19

1 year TSR5 year TSR
4thAvita Medical696%55%
668 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®

Share Transactions

10/01/19
$0 Other
10/01/19
$0 Other
10/01/19
$15k Bought
Total value as at the date of the transaction
Powered by Morningstar ®

Revenue

th-Avita Medical$16.4m
77 listed non wa companies ranked by revenue.
Powered by Morningstar ®